Voyageur Announces Non-Brokered Life Offering
Voyageur Dilutes to Survive as Commercial Revenues Fail to Cover Mounting Feasibility and R&D Costs
The most recent news (March 25, 2026) announces a non-brokered private placement to raise between $4M and $7.5M. The offering consists of units at $0.13 (including a $0.20 warrant) and flow-through shares at $0.17. Proceeds are earmarked for barium inventory, feasibility studies at Frances Creek, U.S. iodine project development, and general corporate purposes. This follows a string of operational updates including a collaboration with Bayer for iodine extraction and the confirmation of 98.8% purity for their Frances Creek barite.
The impact is Routine - Negative. While the funding is necessary for survival, it is highly dilutive. - Dilution: If fully subscribed at the $7.5M cap, the company could issue up to 72.4M new shares (plus warrants), representing a ~40% increase in the share count. - Revenue vs. Burn: Despite "commercial launch" news in 2025, the March 16, 2026 update revealed only C$32,000 in initial sales. This is negligible compared to the $2.6M net loss reported in the 9 months ending August 2025. - Capital Intensity: The company is juggling two "Bankable Feasibility Studies" (BFS) simultaneously. The transition from a junior explorer to a pharmaceutical manufacturer is capital-intensive, and this raise only provides a short-term runway. - Pricing: The $0.13 unit price is a significant discount to the $0.26 highs seen in mid-2025, indicating a weakening of the company's bargaining position with investors.
Voyageur is attempting a "vertical integration" strategy for radiology contrast media. - Flagship Project: Frances Creek (British Columbia), a 100%-owned barite deposit. - Goal: To produce pharmaceutical-grade barium sulfate at $650/tonne vs. synthetic costs of $10,000/tonne. - Secondary Project: Iodine extraction in Oklahoma (partnered with Bayer) and the ULI Project (Utah).